Oncología Médica Traslacional y Terapia Individualizada del Cáncer

Perez-Valderrama, B; Arija, JAA; Sanchez, AR; Marin, AP; Garcia, PB; Gaunas, DEC; Romero, GR; Alonso, CM; Guzman, JCV; Alvarez, JLP; Gonzalez, IC; Vidal, MJM; Fita, MJJ; Leon-Mateos, L; Quintela, ML; Dominguez, RG; Garcia, JMJ; de Mendizabal, EV; Sorrosal, JJL; Carbonero, IG; del Alba, AG; Rodriguez, CS; Gallego, PJ; Garcia, JAM; Marrero, RDG; Borau, PG; Lobera, CS; Palau, CM; Brea, ML; Parra, EMF; Torras, OR; Badiola, LB; Estevez, SV; Larriba, JLG.

Validation of the International Metastatic Renal-Cell Carcinoma Database Consortium (IMDC) prognostic model for first-line pazopanib in metastatic renal carcinoma: the Spanish Oncologic Genitourinary Group (SOGUG) SPAZO study

ANNALS OF ONCOLOGY. 2016; 27(4): 706-711 Nº de citas: 27 [doi:10.1093/annonc/mdv601]

Maroto, P; Solsona, E; Gallardo, E; Mellado, B; Morote, J; Arranz, JA; Gomez-Veiga, F; Unda, M; Climent, MA; Alcaraz, A.

Expert opinion on first-line therapy in the treatment of castration-resistant prostate cancer

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY. 2016; 100: 127-136 Nº de citas: 13 [doi:10.1016/j.critrevonc.2015.07.011]

Puente, J; del Muro, XG; Pinto, A; Lainez, N; Esteban, E; Arranz, JA; Gallardo, E; Mendez, MJ; Maroto, P; Grande, E; Suarez, C.

Expert Recommendations for First-Line Management of Metastatic Renal Cell Carcinoma in Special Subpopulations

TARGETED ONCOLOGY. 2016; 11(2): 129-141 Nº de citas: 4 [doi:10.1007/s11523-015-0408-3]

Gonzalez-Rivera, M; Lobo, M; Lopez-Tarruella, S; Jerez, Y; del Monte-Millan, M; Massarrah, T; Ramos-Medina, R; Ocana, I; Picornell, A; Garzon, SS; Perez-Carbornero, L; Garcia-Saenz, JA; Gomez, H; Moreno, F; Marquez-Rodas, I; Fuentes, H; Martin, M.

Frequency of germline DNA genetic findings in an unselected prospective cohort of triple-negative breast cancer patients participating in a platinum-based neoadjuvant chemotherapy trial

BREAST CANCER RESEARCH AND TREATMENT. 2016; 156(3): 507-515 Nº de citas: 23 [doi:10.1007/s10549-016-3792-1]

Duran, I; Hagen, C; Arranz, JA; Apellaniz-Ruiz, M; Perez-Valderrama, B; Sala, N; Lainez, N; Garcia-Del Muro, X; Nogueron, E; Climent, MA; Maroto, P; Font, A; Garcia-Donas, J; Gallardo, E; Lopez-Criado, P; Del Alba, AG; Saez, MI; Vazquez, S; Luque, R; Rodriguez-Antona, C.

SNPs associated with activity and toxicity of cabazitaxel in patients with advanced urothelial cell carcinoma

PHARMACOGENOMICS. 2016; 17(5): 463-471 Nº de citas: 5 [doi:10.2217/pgs.15.186]

Chan, A; Delaloge, S; Holmes, FA; Moy, B; Iwata, H; Harvey, VJ; Robert, NJ; Silovski, T; Gokmen, E; Von Minckwitz, G; Ejlertsen, B; Chia, SKL; Mansi, J; Barrios, CH; Gnant, M; Buyse, M; Gore, I; Smith, J; Harker, G; Masuda, N; Petrakova, K; Zotano, AG; Iannotti, ZN; Rodriguez, G; Tassone, P; Wong, A; Bryce, R; Ye, YN; Yao, B; Martin, M.

Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

LANCET ONCOLOGY. 2016; 17(3): 367-377 Nº de citas: 479 [doi:10.1016/S1470-2045(15)00551-3]

Pereira, A; Perez-Medina, T; Magrina, JF; Magtibay, PM; Rodriguez-Tapia, A; Cuesta-Guardiola, T; Peregrin, I; Mendizabal, E; Lizarraga, S; Ortiz-Quintana, L.

"The impact of debulking surgery in patients with node-positive epithelial ovarian cancer: Analysis of prognostic factors related to overall survival and progression-free survival after an extended long-term follow-up period"

SURGICAL ONCOLOGY-OXFORD. 2016; 25(1): 49-59 Nº de citas: 6 [doi:10.1016/j.suronc.2015.12.005]

Strasser-Weippl, K; Horick, N; Smith, IE; O'Shaughnessy, J; Ejlertsen, B; Boyle, F; Buzdar, AU; Fumoleau, P; Gradishar, W; Martin, M; Moy, B; Piccart-Gebhart, M; Pritchard, KI; Lindquist, D; Rappold, E; Finkelstein, DM; Goss, PE.

Identification of early breast cancer patient cohorts who may benefit from lapatinib therapy

EUROPEAN JOURNAL OF CANCER. 2016; 56: 85-92 Nº de citas: 4 [doi:10.1016/j.ejca.2015.12.024]

Hadji, P; Coleman, RE; Wilson, C; Powles, TJ; Clezardin, P; Aapro, M; Costa, L; Body, JJ; Markopoulos, C; Santini, D; Diel, I; Di Leo, A; Cameron, D; Dodwell, D; Smith, I; Gnant, M; Gray, R; Harbeck, N; Thurlimann, B; Untch, M; Cortes, J; Martin, M; Albert, US; Conte, PF; Ejlertsen, B; Bergh, J; Kaufmann, M; Holen, I.

Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European Panel

ANNALS OF ONCOLOGY. 2016; 27(3): 379-390 Nº de citas: 134 [doi:10.1093/annonc/mdv617]

Mesia, R; Vazquez, S; Grau, JJ; Garcia-Saenz, JA; Lozano, A; Garcia, C; Carles, J; Irigoyen, A; Manos, M; Garcia-Paredes, B; del Barco, E; Taberna, M; Escobar, Y; Cruz, JJ.

A Phase 2 Open Label, Single-Arm Trial to Evaluate the Combination of Cetuximab Plus Taxotere, Cisplatin, and 5-Flurouracil as an Induction Regimen in Patients With Unresectable Squamous Cell Carcinoma of the Head and Neck

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. 2016; 94(2): 289-296 Nº de citas: 22 [doi:10.1016/j.ijrobp.2015.10.019]

Martin, M; Brase, JC; Ruiz, A; Prat, A; Kronenwett, R; Calvo, L; Petry, C; Bernard, PS; Ruiz-Borrego, M; Weber, KE; Rodriguez, CA; Alvarez, IM; Segui, MA; Perou, CM; Casas, M; Carrasco, E; Caballero, R; Rodriguez-Lescure, A.

Prognostic ability of EndoPredict compared to research-based versions of the PAM50 risk of recurrence (ROR) scores in node-positive, estrogen receptor-positive, and HER2-negative breast cancer. A GEICAM/9906 sub-study

BREAST CANCER RESEARCH AND TREATMENT. 2016; 156(1): 81-89 Nº de citas: 45 [doi:10.1007/s10549-016-3725-z]

Reynes, G; Martinez-Sales, V; Vila, V; Balana, C; Perez-Segura, P; Vaz, MA; Benavides, M; Gallego, O; Palomero, I; Gil-Gil, M; Fleitas, T; Reche, E.

Phase II trial of irinotecan and metronomic temozolomide in patients with recurrent glioblastoma

ANTI-CANCER DRUGS. 2016; 27(2): 133-137 Nº de citas: 11 [doi:10.1097/CAD.0000000000000314]

Masson-Lecomte, A; de Maturana, EL; Goddard, ME; Picornell, A; Rava, M; Gonzalez-Neira, A; Marquez, M; Carrato, A; Tardon, A; Lloreta, J; Garcia-Closas, M; Silverman, D; Rothman, N; Kogevinas, M; Allory, Y; Chanock, SJ; Real, FX; Malats, N; SBC EPICURO Study Investigators.

Inflammatory-Related Genetic Variants in Non-Muscle-Invasive Bladder Cancer Prognosis: A Multimarker Bayesian Assessment

CANCER EPIDEM BIOMAR. 2016; 25(7): 1144-1150 Nº de citas: 3 [doi:10.1158/1055-9965.EPI-15-0894]

De las Penas, R; Ponce, S; Henao, F; Herrero, CC; Carcereny, E; Alvarez, YE; Rodriguez, CA; Virizuela, JA; Lopez, RL.

SIADH-related hyponatremia in hospital day care units: clinical experience and management with tolvaptan

SUPPORTIVE CARE IN CANCER. 2016; 24(1): 499-507 Nº de citas: 11 [doi:10.1007/s00520-015-2948-6]

Stopeck, AT; Fizazi, K; Body, JJ; Brown, JE; Carducci, M; Diel, I; Fujiwara, Y; Martin, M; Paterson, A; Tonkin, K; Shore, N; Sieber, P; Kueppers, F; Karsh, L; Yardley, D; Wang, H; Maniar, T; Arellano, J; Braun, A.

Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer

SUPPORTIVE CARE IN CANCER. 2016; 24(1): 447-455 Nº de citas: 146 [doi:10.1007/s00520-015-2904-5]

Lipton, A; Fizazi, K; Stopeck, AT; Henry, DH; Smith, MR; Shore, N; Martin, M; Vadhan-Raj, S; Brown, JE; Richardson, GE; Saad, F; Yardley, DA; Zhou, K; Balakumaran, A; Braun, A.

Effect of denosumab versus zoledronic acid in preventing skeletal-related events in patients with bone metastases by baseline characteristics

EUROPEAN JOURNAL OF CANCER. 2016; 53: 75-83 Nº de citas: 94 [doi:10.1016/j.ejca.2015.09.011]

Martinez, MT; Perez-Fidalgo, JA; Martin-Martorell, P; Cejalvo, JM; Pons, V; Bermejo, B; Martin, M; Albanell, J; Lluch, A.

Treatment of HER2 positive advanced breast cancer with T-DM1: A review of the literature

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY. 2016; 97: 96-106 Nº de citas: 48 [doi:10.1016/j.critrevonc.2015.08.011]

Gayarre, J; Kamieniak, MM; Cazorla-Jimenez, A; Munoz-Repeto, I; Borrego, S; Garcia-Donas, J; Hernando, S; Robles-Diaz, L; Garcia-Bueno, JM; Cajal, TRY; Hernandez-Agudo, E; Soto, VH; Marquez-Rodas, I; Echarri, MJ; Lacambra-Calvet, C; Saez, R; Cusido, M; Redondo, A; Paz-Ares, L; Hardisson, D; Mendiola, M; Palacios, J; Benitez, J; Garcia, MJ.

The NER-related gene GTF2H5 predicts survival in high-grade serous ovarian cancer patients

Journal of Gynecologic Oncology. 2016; 27(1): Nº de citas: 18 [doi:10.3802/jgo.2016.27.e7]